<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538250</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1422</org_study_id>
    <nct_id>NCT02538250</nct_id>
  </id_info>
  <brief_title>Acceptability Study on Oral Nutrition Supplement (ONS)</brief_title>
  <official_title>Acceptability Study on Nutricomp Drink Plus in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Required for Advisory Committee for Borderline Substances (ACBS) approval. Aim of this study
      is to access the palatability, compliance and GI-tolerance of Nutricomp® Drink Plus to show
      that it is acceptable for patients in the United Kingdom.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of gastrointestinal tolerance parameters (Diarrhoea, Constipation, Bloating, Distension, Nausea, Vomiting, Burping, Regurgitation, Flatulence, Abdominal discomfort, Abdominal pain, Other (further gastrointestinal adverse events)</measure>
    <time_frame>7 days</time_frame>
    <description>Parameters asked as required for acceptability studies by Advisory Committee for Borderline Substances- documented in a patient diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of further adverse effects</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of palatability by questionnaire</measure>
    <time_frame>1 day</time_frame>
    <description>Five point hedonic scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of compliance.</measure>
    <time_frame>7 days</time_frame>
    <description>Comparison of prescription and actual intake</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Oral Nutritional Supplementation</condition>
  <arm_group>
    <arm_group_label>1 Nutricomp Drink Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutricomp Drink Plus</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutricomp Drink Plus</intervention_name>
    <description>Oral nutritional supplementation</description>
    <arm_group_label>1 Nutricomp Drink Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Male and female patients

          -  ≥ 18 years of age

          -  Patients of the intended target group (e.g. MUST score ≥ 1) with an anticipated period
             of nutritional support ≥ 7 days

          -  Patient is able and willing to provide written informed consent

        Exclusion:

          -  Hypersensitivity to milk, whey, soy, fish or any of the active substances or
             excipients

          -  Patients with available or potential impairment of sense of taste or smell due to
             disease (e.g. patients with cold, cancer patients) or medication (e.g.
             D-Penicillamine)

          -  Patients who express general dislike to two or more of the four flavours

          -  Severely impaired gastrointestinal function or complete failure

          -  Severe metabolic or circulatory disorders

          -  Acute disease

          -  Unstable vital functions

          -  Necessity of total parenteral nutrition or more than 50% Parenteral Nutrition in
             combined therapy

          -  Simultaneous participation in another interventional study

          -  Patients who are unwilling or mentally and/or physically unable to adhere to study
             procedures

          -  Pregnancy

          -  Emergencies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Sanders, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Hallamshire Hospital,Regional Gastrointestinal and Liver Unit, Sheffield, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust, The Royal Hallamshire Hospital, Regional Gastrointestinal and Liver Unit</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral nutritional supplement</keyword>
  <keyword>supplementation</keyword>
  <keyword>adult patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

